Seres Therapeutics
MCRB
123 hedge funds and large institutions have $313M invested in Seres Therapeutics in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 49 reducing their positions, and 23 closing their positions.
20% more call options, than puts
Call options by funds: $788K | Put options by funds: $659K
0.83% more ownership
Funds ownership: 4.1% → 4.93% (+0.83%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 131 → 123 (-8)
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
31% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 49
42% less capital invested
Capital invested by funds: $535M → $313M (-$222M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$43M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$20.3M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$11.7M |
| 4 |
MS
Maven Securities
St Helier,
Jersey
|
+$4.97M |
| 5 |
JP Morgan Chase
New York
|
+$2.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$14.6M |
| 2 |
SAM
Soviero Asset Management
New York
|
-$2.56M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.14M |
| 4 |
Rafferty Asset Management
New York
|
-$2.11M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$2M |
MCRB Hedge Fund Activity: Q2 2022 in Review
123 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q2 2022, worth a combined $313M — down 42% from $535M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of MCRB and 18 opened new positions — a net loss of 5 holders — while 49 trimmed existing stakes and 34 added.
The largest buyer was Federated Hermes, adding an estimated $43M. The largest seller was State Street, cutting an estimated $14.6M.
- 123 institutional investors held Seres Therapeutics (MCRB) as of Q2 2022, down from 131 in Q1 2022.
- Funds reported $313M of Seres Therapeutics stock for Q2 2022, down 42% quarter-over-quarter.
- 18 funds opened new Seres Therapeutics positions in Q2 2022 and 23 closed out, a net change of -5 holders.
- The largest Seres Therapeutics buyer in Q2 2022 was Federated Hermes, an estimated $43M added.
- The largest Seres Therapeutics seller in Q2 2022 was State Street, an estimated $14.6M sold.
Based on aggregated 13F filings for Q2 2022.